REFERENCES
- Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregion-ally advanced head and neck cancer: 5-year survival data from a phase 3 ran-domised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2009; 11: 21–28.
- Tobias JS, Manson K, Gupta N, et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol 2010; 11: 66–74.
- Gregoire V, Lefebvre J-L, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treat-ment, and follow-up. Ann Oncol 2010; 21 (suppl 5): v 184–186.
- Eriksen JG, Lassen P, Overgaard J. Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab? Lancet Oncol 2010; 11: 312–313.
- Bernier J, Russi EG, Homey B, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squa-mous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol 2011; 22: 2191–2200.
- Kar S, Adachi T, Carr BI. EGFR-independent activation of ERK1/2 mediates growth inhibition by a PTPase antagonizing K-vitamin analog. J Cell Physiol 2002; 190: 356–364.
- Perez-Soler R, Zou Y, Li T, Ling YH. The phosphatase inhitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab. Clin Cancer Res 2011; 17:6766–6777.
- Ocvirk J, Rebersek M. Management of cutaneous side effects of cetuximab therapy with vitamin K1 creme. Radio/ Oncol 2008; 42: 215–224.
- Gregoire V. Daisne JF, Geets X, Leventrag P. Selection and delineation of target volumes in head and neck tumors: beyond ICRU definition. Rays 2003; 28:217–224.
- Gregoire V. Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol 2006; 79: 15–20.
- Pignon J-P, le Maitre A, Maillard A, Bourhis J, on behalf of the MACH-NC Col-laborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update of 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92,4–14.
- Brummel-Ziedins K, Orfeo T, Swords Jenny N, Everse SJ, Mann KG. Blood coagu-lation and fibrinolysis. In: Greer JP, Foerster J, Lukens JN, Rodgers GM, Paraskevas F, Glader B, eds. Wintrobe's Clinical Hematology, 11th Edition, Philadelphia: Lippincott Williams & Wilkins 2004; 687–693.
- Giaccone G, Zucali P. Signal transduction inhibitors, HER family, EGFR inhibition, and clinical achievements. In: Giaccone G, Soria J-C, eds. Targeted Therapies in Oncology. Informa Healthcare, USA, 2007; 19–44.